Effect of rechallenge nivolumab in a hemodialysis patient with multiple metastases from a rapidly progressed T1a renal clear cell carcinoma: An autopsy case

Introduction Distant metastasis of T1a renal cell carcinoma is rare and whether metastasis is more probable in patients undergoing hemodialysis remains unclear. We report the autopsy case of a patient undergoing hemodialysis with multiple metastases that rapidly progressed from T1a renal cell carcin...

Full description

Saved in:
Bibliographic Details
Published in:IJU case reports 2024-05, Vol.7 (3), p.202-205
Main Authors: Hanawa, Kazushi, Sawada, Norifumi, Yokota, Yuka, Aikawa, Junki, Otake, Yuko, Sugimura, Koki, Shimura, Hiroshi, Mochizuki, Takanori, Kira, Satoru, Mitsui, Takahiko
Format: Article
Language:English
Subjects:
Autopsies
autopsy
Cancer therapies
Case Report
Case Reports
Conflicts of interest
Ethics
Hemodialysis
Immunotherapy
Kidney cancer
Kinases
Laparoscopy
Medical prognosis
Metastasis
Monoclonal antibodies
nivolumab
Pathology
Patients
Supervision
T1a renal cell carcinoma
Targeted cancer therapy
Tumors
Visualization
Writing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Distant metastasis of T1a renal cell carcinoma is rare and whether metastasis is more probable in patients undergoing hemodialysis remains unclear. We report the autopsy case of a patient undergoing hemodialysis with multiple metastases that rapidly progressed from T1a renal cell carcinoma treated with multimodal therapy including nivolumab. Case presentation A 70‐year‐old male who underwent hemodialysis was diagnosed with clear cell carcinoma (pT1a, G2) after nephrectomy. Six months post‐surgery, bone and lung metastases appeared and treated with radiotherapy and pazopanib, respectively. Nivolumab was administered as second‐ and fourth‐line treatments for lung metastases. The patient died approximately 60 months after initial diagnosis; however, nivolumab controlled disease progression for 24 months. An autopsy revealed the lung's occupation with clear cell carcinoma tumor tissue. Conclusion Nivolumab has potential to control lung metastasis progression. Additionally, rechallenge is possible in patients with renal cell carcinoma undergoing hemodialysis.
ISSN:2577-171X
2577-171X
DOI:10.1002/iju5.12699